Literature DB >> 2470989

Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle.

P J Silver1, A L Harris, P C Canniff, R E Lepore, R G Bentley, L T Hamel, D B Evans.   

Abstract

The purpose of the present study was to examine the interrelationships among phosphodiesterase (PDE) isozyme inhibition, cAMP formation, activation of cAMP-dependent protein kinase (cAPK), and positive inotropy in isolated guinea pig cardiac muscle mediated by the cardiotonic/vasodilator agent, milrinone. Milrinone was a potent and selective inhibitor of the "low Km" cAMP PDE isozyme (peak III) isolated by diethylaminoethyl ether cellulose chromatography, with IC50 values of 0.7 microM for peak III PDE and 100 microM for peak I PDE. In isolated papillary muscles frozen at peak inotropic responses, positive and significant correlations were evident between isometric force development as a function of cAMP content (r = 0.72, p less than 0.05) or cAPK activity ratio, an index of activation of cAPK (r = 0.79, p less than 0.001), for concentrations of milrinone from 0.1-1000 microM. Similar correlations were evident in muscles frozen at peak inotropic responses for the beta-adrenoreceptor agonist isoproterenol (r = 0.96, p less than 0.001; r = 0.98, p less than 0.001, respectively), but not for ouabain or Bay K-8644. The temporal sequence of these events was also quantitated for concentrations of milrinone (100 microM) and isoproterenol (3 nM) that produced approximately a 100% increase in isometric force. Whereas early time interval of force development (30 s, 1 min, isoproterenol; 30 s milrinone) were not accompanied by significant increases in either cAMP content or cAPK activity ratio, peak increases in force development for both isoproterenol (2 min) and milrinone (1 min) were related to peak increases in cAPK activity ratios. In summary, these results show that significant increases in cAMP content or cAPK activation are correlated with positive inotropy in isolated guinea pig papillary muscles with milrinone. These correlations occur at concentrations of milrinone that inhibit cardiac PDE isozymes and are similar to the known cAMP-dependent cardiostimulant isoproterenol. These data support the hypothesis that selective PDE isozyme inhibition is a mechanism by which milrinone effects positive inotropy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470989

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

Authors:  M A Movsesian; C J Smith; J Krall; M R Bristow; V C Manganiello
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series.

Authors:  A T James; C Bee; J D Corcoran; P J McNamara; O Franklin; A F El-Khuffash
Journal:  J Perinatol       Date:  2014-11-27       Impact factor: 2.521

3.  Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.

Authors:  M Shahid; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

4.  Use of milrinone in the management of haemodynamic instability following duct ligation.

Authors:  Arvind Sehgal; Johny V Francis; Anthony I Lewis
Journal:  Eur J Pediatr       Date:  2010-09-17       Impact factor: 3.183

5.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

6.  Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts.

Authors:  W Zimmermann; H Scholz; C Schumacher; H Wenzlaff; A Haverich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

Review 7.  Inotropes for Preterm Infants: 50 Years on Are We Any Wiser?

Authors:  Aisling A Garvey; Elisabeth M W Kooi; Eugene M Dempsey
Journal:  Front Pediatr       Date:  2018-04-06       Impact factor: 3.418

Review 8.  The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1): study protocol and review of literature.

Authors:  Afif El-Khuffash; Patrick J McNamara; Colm Breatnach; Neidin Bussmann; Aisling Smith; Oliver Feeney; Elizabeth Tully; Joanna Griffin; Willem P de Boode; Brian Cleary; Orla Franklin; Eugene Dempsey
Journal:  Matern Health Neonatol Perinatol       Date:  2018-12-03

9.  Short-term ventriculo-arterial coupling and myocardial work efficiency in preterm infants undergoing percutaneous patent ductus arteriosus closure.

Authors:  Adrianne R Bischoff; Amy H Stanford; Patrick J McNamara
Journal:  Physiol Rep       Date:  2021-11

10.  Effects of milrinone on serum IL-6, TNF-α, Cys-C and cardiac functions of patients with chronic heart failure.

Authors:  Tingguo Shao; Yuqing Zhang; Rubo Tang; Hai Zhang; Quanzheng Wang; Ying Yang; Tongxiang Liu
Journal:  Exp Ther Med       Date:  2018-08-31       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.